M
Mary Rose Rogers
Researcher at University of Chicago
Publications - 8
Citations - 869
Mary Rose Rogers is an academic researcher from University of Chicago. The author has contributed to research in topics: Mesenchymal stem cell & Cellular differentiation. The author has an hindex of 6, co-authored 7 publications receiving 729 citations.
Papers
More filters
Journal ArticleDOI
Wnt signaling in bone formation and its therapeutic potential for bone diseases
Jeong Hwan Kim,Xing Liu,Jinhua Wang,Xiang Chen,Hongyu Zhang,Stephanie H. Kim,Jing Cui,Ruidong Li,Wenwen Zhang,Yuhan Kong,Jiye Zhang,Wei Shui,Joseph D. Lamplot,Mary Rose Rogers,Chen Zhao,Ning Wang,Prashant Rajan,Justin Tomal,Joseph Statz,Ningning Wu,Hue H. Luu,Rex C. Haydon,Tong-Chuan He +22 more
TL;DR: The present review discusses the role of the Wnt signaling pathway in osteogenesis and examines its targeted therapeutic potential and indicates it requires cautious approach due to risks of tumorigenesis.
Journal ArticleDOI
BMP signaling in mesenchymal stem cell differentiation and bone formation.
Maureen Beederman,Joseph D. Lamplot,Guoxin Nan,Jinhua Wang,Xing Liu,Liangjun Yin,Ruidong Li,Wei Shui,Hongyu Zhang,Stephanie H. Kim,Wenwen Zhang,Jiye Zhang,Yuhan Kong,Sahitya K. Denduluri,Mary Rose Rogers,Abdullah Pratt,Rex C. Haydon,Hue H. Luu,Jovito Angeles,Lewis L. Shi,Tong-Chuan He +20 more
TL;DR: Current knowledge of BMP-mediated osteogenesis is summarized, with a focus on BMP9, by presenting recently completed work which may help to further elucidate these pathways.
Journal ArticleDOI
BMP9 signaling in stem cell differentiation and osteogenesis.
Joseph D. Lamplot,Jiaqiang Qin,Guoxin Nan,Jinhua Wang,Xing Liu,Liangjun Yin,Justin Tomal,Ruidong Li,Wei Shui,Hongyu Zhang,Stephanie H. Kim,Wenwen Zhang,Jiye Zhang,Yuhan Kong,Sahitya K. Denduluri,Mary Rose Rogers,Abdullah Pratt,Rex C. Haydon,Hue H. Luu,Jovito Angeles,Lewis L. Shi,Tong-Chuan He +21 more
TL;DR: In this paper, the authors summarize the current knowledge of BMP9-mediated osteogenesis by presenting recently completed work which may help us to further elucidate these pathways, and they conclude that BMP-9 is known to be a potent osteogenic factor, it also influences several other pathways including cancer development, angiogenesis and myogenesis.
Journal ArticleDOI
BMP9-regulated angiogenic signaling plays an important role in the osteogenic differentiation of mesenchymal progenitor cells
Ning Hu,Dianming Jiang,Enyi Huang,Enyi Huang,Xing Liu,Xing Liu,Ruidong Li,Ruidong Li,Xi Liang,Xi Liang,Stephanie H. Kim,Xiang Chen,Xiang Chen,Jian-Li Gao,Jian-Li Gao,Hongyu Zhang,Hongyu Zhang,Wenwen Zhang,Wenwen Zhang,Yuhan Kong,Yuhan Kong,Jiye Zhang,Jiye Zhang,Jinhua Wang,Jinhua Wang,Wei Shui,Wei Shui,Xiaoji Luo,Xiaoji Luo,Bo Liu,Bo Liu,Jing Cui,Jing Cui,Mary Rose Rogers,Jikun Shen,Chen Zhao,Chen Zhao,Ning Wang,Ning Wang,Ningning Wu,Ningning Wu,Hue H. Luu,Rex C. Haydon,Tong-Chuan He,Wei Huang +44 more
TL;DR: These findings should not only expand the understanding of the molecular basis behind BMP9-regulated osteoblastic lineage-specific differentiation, but also provide an opportunity to harness the B MP9-induced synergy between osteogenic and angiogenic signaling pathways in regenerative medicine.
Journal ArticleDOI
Cross-talk between EGF and BMP9 signalling pathways regulates the osteogenic differentiation of mesenchymal stem cells
Xing Liu,Jiaqiang Qin,Jiaqiang Qin,Qing Luo,Qing Luo,Yang Bi,Yang Bi,Gao-Hui Zhu,Gao-Hui Zhu,Wei Jiang,Stephanie H. Kim,Mi Li,Mi Li,Yuxi Su,Yuxi Su,Guoxin Nan,Guoxin Nan,Jing Cui,Jing Cui,Wenwen Zhang,Wenwen Zhang,Ruidong Li,Ruidong Li,Xiang Chen,Xiang Chen,Yuhan Kong,Yuhan Kong,Jiye Zhang,Jiye Zhang,Jinhua Wang,Jinhua Wang,Mary Rose Rogers,Hongyu Zhang,Hongyu Zhang,Wei Shui,Wei Shui,Chen Zhao,Chen Zhao,Ning Wang,Ning Wang,Xi Liang,Xi Liang,Ningning Wu,Ningning Wu,Yunfeng He,Yunfeng He,Hue H. Luu,Rex C. Haydon,Lewis L. Shi,Tingyu Li,Tong-Chuan He,Tong-Chuan He,Ming Li +52 more
TL;DR: It is found that EGF potentiates BMP9‐induced early and late osteogenic markers of MSCs in vitro, which can be effectively blunted by EGFR inhibitors Gefitinib and Erlotinib or receptor tyrosine kinase inhibitors AG‐1478 and AG‐494 in a dose‐ and time‐dependent manner.